High levels of Type III von Willebrand Disease, a serious, hereditary
bleeding disorder, found in region
KING OF PRUSSIA, Pa., Dec. 19 /PRNewswire/ -- CSL Behring today announced that Iran's Ministry of Health and Medical Education (MOHME) has granted rights to the company to distribute Haemate(R) P on an exclusive basis throughout Iran, beginning immediately. Haemate P is indicated for the treatment of von Willebrand Disease, a serious, hereditary, and sometimes life-threatening condition caused by a deficiency or abnormality of the von Willebrand factor, a protein in the blood that is necessary for normal blood clotting. Women with some forms of von Willebrand Disease (VWD) are at greater risk for miscarriage, life-threatening bleeding following surgery and childbirth, and for undergoing unnecessary hysterectomies.
CSL Behring will be the first and only company to bring VWD treatment to Iran this year, where the incidence of the condition is reportedly up to 10 times higher than in other areas of the world.
"By introducing Haemate P into Iran, CSL Behring is offering many Type
III VWD patients a safe, effective alternative to treating a health
condition that can have a significant impact on a patient's quality of
life, and that, at times, can even be life-threatening," said Paul
Perreault, Executive Vice President of Worldwide Commercial Operations at
CSL Behring. "Our company's mission to help those whose lives are affected
by serious medical disorders is being fulfilled through the excellent
collaboration we have achieved with the MOHME. We look forward to
continuing this partnership and to finding new ways to support efforts to
bring safe, effective plasma-derived therapies to the region." Perreault
added that, while Factor VIII and IX concentrate products are widely used
and accessible in Iran, no specific von Willebrand product or VWD treatment
guidelines were available there. Instead, cryoprecipitate has been
|SOURCE CSL Behring|
Copyright©2007 PR Newswire.
All rights reserved